Is Pirfenidone/Isrifen domestically produced or imported?

Pirfenidone/Pirfenidone was originally developed by a foreign pharmaceutical company and was first approved for the treatment of idiopathic pulmonary fibrosis (IPF) in the early 2000s. With the clinical application of this drug around the world, its efficacy has gradually been recognized and it has quickly entered the market in many countries and regions.

In China, Isri was approved by the State Food and Drug Administration in 2017 and became the first drug to treat idiopathic pulmonary fibrosis. The introduction of this drug provides new treatment options for IPF patients in my country and improves their quality of life. Before approval, Chinese patients mostly relied on some symptomatic treatments and lacked effective anti-fibrotic drugs, so the launch of Isri is of great significance.

In addition to original drugs, with the increase in market demand and the accumulation of relevant clinical experience, some domestic pharmaceutical companies have also begun to develop generic drugs of pirfenidone in recent years. On the basis of complying with relevant laws and standards, these domestic generic drugs strive to be equivalent to the original drugs in terms of efficacy and safety. The launch of domestically produced pirfenidone can not only reduce the cost of treatment for patients, but also improve the accessibility of the drug, especially for those patients with limited financial conditions.

Although domestically produced pirfenidone has certain advantages in price, in actual treatment, doctors and patients still need to pay attention to the manufacturer of the drug, the quality control of the drug, and the consistency of its clinical effects. Because slight differences in the production process and formula of the drug may affect the bioavailability and efficacy of the drug, thereby affecting the patient's therapeutic effect. Therefore, when choosing to use, doctors usually make reasonable medication recommendations based on the patient's specific situation and the source of the drug.